Journey was Fortress Biotech’s largest segment in fiscal 2025, bringing in $123.72M of $126.52M (98%).
| Segment | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Journey | $112.27M | $123.72M | |||||||
| Dermatology Products Sales | — | — | |||||||
| Financial Service Activities | — | — | |||||||
| Pharmaceutical & Biotechnology Product Development | — | — | |||||||
| Avenue | — | $2.81M | |||||||
| Checkpoint Merger | $82.00K | — | |||||||
| Total | $112.35M | $126.52M |
Fortress Biotech brought in $126.52M from its two segments in fiscal 2025, the year ended December 31, 2025. Fortress Biotech regrouped these segments after fiscal 2024, so the total does not compare directly with that year's $112.35M. Journey was the largest at $123.72M (97.8%), ahead of Avenue at $2.81M (2.2%).
Fortress Biotech began breaking out Avenue in fiscal 2025, when it brought in $2.81M. Fortress Biotech stopped reporting Checkpoint Merger as a separate segment after fiscal 2024, when it brought in $82.00K.
Qbrexza was Fortress Biotech’s largest product and service line in fiscal 2024, bringing in $50.23M of $110.27M (46%).
| Product and Service | FY 2018 | FY 2019 | FY 2024 |
|---|---|---|---|
| Qbrexza | $50.23M | ||
| Targadox | — | ||
| Accutane | $38.81M | ||
| Foam Franchise Products (Amzeeq Zilxi) | $13.30M | ||
| Other / Legacy Product Revenue | $7.92M | ||
| Ximino | — | ||
| Return Reserve | — | ||
| License & Service | — | ||
| Other Branded Revenue | — | ||
| Royalty | — | ||
| Total | $110.27M |
Fortress Biotech brought in $110.27M from its four product and service lines in fiscal 2024, the year ended December 31, 2024. Qbrexza was the largest at $50.23M (45.6%), ahead of Accutane at $38.81M (35.2%) and Foam Franchise Products (Amzeeq Zilxi) at $13.30M (12.1%). The remaining line, Other / Legacy Product Revenue, brought in $7.92M.
Fortress Biotech (FBIO) reports its revenue by segment and by product and service. In fiscal 2025, Journey was its largest segment, bringing in $123.72M (97.8% of the total), followed by Avenue at $2.81M (2.2%).
Journey was Fortress Biotech's largest segment in fiscal 2025, bringing in $123.72M, or 97.8% of the $126.52M total across its two segments.
Qbrexza was Fortress Biotech's largest product and service line in fiscal 2024, bringing in $50.23M, or 45.6% of the $110.27M total across its four product and service lines.
Every figure comes from Fortress Biotech's annual financial filings, as reported. Each line keeps the name Fortress Biotech gives it, and years follow its fiscal calendar.
Fortress Biotech's revenue by segment goes back to fiscal 2015, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.